Financial Performance - For Q4 2025, ECB Bancorp reported net income of $2.6 million, or $0.31 per diluted share, up from $1.4 million, or $0.17 per diluted share in Q4 2024, representing an increase of 85.7%[2] - Net income for the year ended December 31, 2025, was $7,772 thousand, a significant increase of 94.3% compared to $3,991 thousand in 2024[23] - Basic earnings per share rose to $0.96 for the year ended December 31, 2025, compared to $0.48 in 2024, reflecting a 100% increase[23] Loan and Deposit Growth - Total loans increased by $237.0 million, or 20.7% year-over-year, while total deposits grew by $133.8 million, or 13.4% over the same period[3] - Total deposits grew to $1,132,344 thousand in 2025, up 13.4% from $998,533 thousand in 2024[21] Income and Revenue - Net interest and dividend income before provision for credit losses was $9.2 million for Q4 2025, an increase of $2.4 million, or 34.9% from $6.8 million in Q4 2024[4] - Net interest and dividend income after provision for credit losses was $30,383 thousand for the year ended December 31, 2025, an increase of 22.3% from $24,814 thousand in 2024[23] - Interest and fees on loans increased to $69,085 thousand in 2025, up 19.5% from $57,852 thousand in 2024[23] - Total noninterest income for the year ended December 31, 2025, was $1,326 thousand, a 8.2% increase from $1,226 thousand in 2024[23] - Noninterest income for Q4 2025 was $360,000, up $33,000, or 10.1% from $327,000 in Q4 2024[6] Asset and Equity Growth - Total assets increased by $187.5 million, or 13.2%, to $1.61 billion at December 31, 2025, from $1.42 billion at December 31, 2024[10] - Total assets increased to $1,605,653 thousand as of December 31, 2025, up from $1,418,153 thousand in 2024, representing a growth of 13.2%[21] - Total shareholders' equity increased by $3.7 million, or 2.2%, to $171.9 million as of December 31, 2025, from $168.3 million as of December 31, 2024[15] - Book value per common share increased to $19.55 as of December 31, 2025, compared to $18.50 in 2024, reflecting a growth of 5.7%[21] Credit Quality - The allowance for credit losses on loans was $10.3 million, or 0.74% of total gross loans, as of December 31, 2025, compared to $8.9 million, or 0.78%, as of December 31, 2024[16] - The company recorded net charge-offs of $86,000 for the year ended December 31, 2025, compared to $3,000 for the year ended December 31, 2024[16] Future Plans - ECB Bancorp plans to expand its footprint with the opening of a new branch in Medford, MA in 2026[3] Expense Management - Total noninterest expense for the year ended December 31, 2025, was $21,330 thousand, an increase of 3.2% from $20,669 thousand in 2024[23] Capital Ratios - The Tier 1 capital to risk-weighted assets ratio decreased to 13.34% in 2025 from 15.56% in 2024[21] Margin Analysis - The net interest margin expanded by 38 basis points to 2.32% for Q4 2025, compared to 1.94% for Q4 2024[4]

Exhibit 99.1 Parent of CFBank, NA PRESS RELEASE FOR IMMEDIATE RELEASE: February 5, 2026 Recent Developments • On January 5, 2026, the Company's Board of Directors declared a cash dividend of $0.09 per share on its Common Stock and a corresponding cash dividend of $9.00 per share on its Series D Preferred Stock. The dividend was paid on January 26, 2026 to shareholders of record as of the close of business on January 15, 2026. CEO and Board Chair Commentary Timothy T. O'Dell, President and CEO, commented "Ou ...

Exhibit 99.1 • The Company recorded net income of $0.6 million for the second quarter of fiscal 2026, a 4.9% increase from the same period of the prior year. • Income before taxes increased by 12.1% to $0.8 million for the second quarter of fiscal 2026 compared to the same period of the prior year. • Total revenue increased by $0.2 million to $3.0 million for the second quarter of fiscal 2026 compared to the same period of the prior year, a 6.0% increase. • Adjusted EBITDA increased by $0.1 million to $0.9 ...

Policy Submissions and Approvals - Total submitted policies for all products increased by 1% for the three months ended December 31, 2025, compared to the same period in 2024, primarily due to a 7% increase in the number of average productive agents[185]. - Total approved policies for all products increased by 4% for the three months ended December 31, 2025, compared to the same period in 2024, correlating with the increase in submitted policies[190]. - Medicare Advantage plans accounted for 93% of approved Senior policies for the three months ended December 31, 2025, consistent with the previous year[178]. - Total approved policies decreased by 5% for the six months ended December 31, 2025, compared to the same period in 2024, correlating with the decrease in submitted policies[191]. Membership and Growth - The total number of SelectRx members increased by 17% as of December 31, 2025, compared to December 31, 2024, reflecting the company's strategy to grow SelectRx membership[197]. - Average prescriptions shipped per day increased to 32,578 for the three months ended December 31, 2025, compared to 26,846 for the same period in 2024[198]. - The number of SelectRx members increased by 17% over the prior year, contributing to the rise in medication and fulfillment costs[216]. Revenue and Income - Total revenue for the three months ended December 31, 2025, was $537,102,000, a 12% increase from $481,069,000 in the prior year[203]. - Pharmacy revenue increased by 26% to $227,209,000 for the three months ended December 31, 2025, primarily due to a 17% increase in members[207]. - Operating income for the three months ended December 31, 2025, was $75,311,000, representing a 6% increase from $70,940,000 in the prior year[203]. - Net income for the three months ended December 31, 2025, was $69,293,000, a 30% increase from $53,236,000 in the prior year[203]. - Total consolidated revenue for the three months ended December 31, 2025, was $537.1 million, an increase from $481.1 million in the same period of 2024, representing a year-over-year growth of approximately 11.7%[241][247]. Expenses and Costs - Cost of goods sold for pharmacy revenue increased by 31% to $205,194,000 for the three months ended December 31, 2025, mainly due to a $47.2 million rise in medication costs[214]. - Marketing and advertising expenses increased by $7.3 million, or 7%, for the three months ended December 31, 2025, primarily due to a $5.8 million increase in lead costs[218]. - Selling, general, and administrative expenses decreased by $6.1 million, or 14%, for the three months ended December 31, 2025, primarily due to a $6.3 million decrease in corporate development costs[222]. - Cost of commissions and other services revenue increased by 2% to $103,034,000 for the three months ended December 31, 2025, primarily due to a rise in compensation costs[211]. Segment Performance - Healthcare Services segment generated external revenue of $259.2 million for the three months ended December 31, 2025, up from $253.8 million in the same period of 2024, reflecting a growth of approximately 2.7%[241][247]. - Senior segment reported external revenue of $230.4 million for the three months ended December 31, 2025, compared to $183.3 million in the same period of 2024, marking a significant increase of about 25.7%[241][247]. - Revenue from Healthcare Services increased by $112.9 million, or 33%, to $452.0 million for the six months ended December 31, 2025, driven by a 17% increase in SelectRx members[268]. - Revenue from Senior decreased by $28.0 million, or 8%, to $320.5 million for the six months ended December 31, 2025, primarily due to a $24.1 million decrease in commission revenue[269]. Financial Position and Debt - The Company had total debt obligations of $405.8 million as of December 31, 2025, up from $385.1 million as of June 30, 2025[286]. - The Company entered into a new $415.0 million credit facility on January 8, 2026, which includes a $325.0 million senior secured term loan and a revolving credit facility of up to $90.0 million[284]. - As of December 31, 2025, the Company had $23.3 million in cash, cash equivalents, and restricted cash, down from $37.1 million as of June 30, 2025[287]. Adjusted EBITDA - Adjusted EBITDA for the three months ended December 31, 2025, was $84.7 million, compared to $87.5 million for the same period in 2024[234]. - Adjusted Segment EBITDA for the three months ended December 31, 2025, was $108.9 million, compared to $110.2 million for the same period in 2024, indicating a slight decrease of about 1.2%[242][248]. - Adjusted EBITDA from Senior for the six months ended December 31, 2025, was $81.4 million, a decrease of $26.8 million compared to the prior year[274]. - Adjusted EBITDA from Healthcare Services increased to $8.1 million for the six months ended December 31, 2025, reflecting a $112.9 million revenue increase, despite a $111.8 million rise in cost of goods sold[275]. Impairments and Charges - The Company recognized an impairment charge of $1.0 million during the three months ended December 31, 2025, representing a full write-off of its equity-method investment[246][257]. Interest and Tax Expenses - Interest expense decreased by $12.1 million, or 51%, for the three months ended December 31, 2025, primarily driven by a lower cost of capital following the completion of the securitization transaction[227]. - Income tax expense for the three months ended December 31, 2025, was $13.7 million, with an effective tax rate of 16.5%[229].

Sales Performance - Total domestic retail sales for Pizza Inn increased by $1.1 million, or 4.1%, for the three months ended December 28, 2025 compared to the same period of the prior year [83]. - Total domestic retail sales for Pizza Inn increased by $3.6 million, or 7.1%, for the six months ended December 28, 2025 compared to the same period of the prior year [84]. - Comparable store retail sales for Pizza Inn increased by $0.6 million, or 2.5%, for the three months ended December 28, 2025 compared to the same period of the prior fiscal year [83]. - Pie Five total domestic retail sales decreased by $0.4 million, or 16.3%, for the three months ended December 28, 2025 compared to the same period of the prior year [88]. - Pie Five total domestic retail sales decreased by $1.0 million, or 17.6%, for the six months ended December 28, 2025 compared to the same period of the prior year [89]. - Average units open decreased from 18 to 16, contributing to a comparable store retail sales decrease of $0.3 million, or 5.7% for the same six-month period [89]. Unit Count - The number of domestic Pizza Inn units increased by one during the three and six months ended December 28, 2025, totaling 97 units [85]. - The number of international Pizza Inn units decreased by one during the three months ended December 28, 2025, totaling 19 units [87]. - Average Buffet Units open in the period increased from 78 to 80 for the three months ended December 28, 2025 [83]. - The average number of Pie Five units open in the period decreased from 18 to 16 for the three months ended December 28, 2025 [88]. Financial Performance - Adjusted EBITDA for the fiscal quarter ended December 28, 2025 increased by $0.1 million compared to the same period of the prior fiscal year, reaching $852,000 [79]. - EBITDA for the fiscal quarter ended December 28, 2025 was $793,000, an increase from $717,000 in the same period of the prior year [81]. - Total revenues for the three-month period ended December 28, 2025 were $3.0 million, an increase from $2.9 million in the prior fiscal year [95]. - Total revenues for the six-month period ended December 28, 2025 were $6.3 million, compared to $5.9 million in the same period of the prior fiscal year [95]. - Pizza Inn franchise revenues increased by $0.3 million to $2.8 million for the three-month period ended December 28, 2025, a 10.5% increase driven by higher system-wide retail sales [96]. - Pie Five franchise revenues decreased by $0.1 million to $0.2 million for the three-month period ended December 28, 2025, a 21.7% decrease due to lower system-wide retail sales [98]. Expenses - Total general and administrative expenses increased by $0.2 million for the three-month period ended December 28, 2025, a 15.6% increase driven by higher salaries [99]. - Total franchise expenses decreased by $0.1 million to $0.7 million for the three-month period ended December 28, 2025, an 11.7% decrease due to lower salaries related to franchise operations [100]. - Depreciation and amortization expense decreased by $11 thousand to $42 thousand for the three-month period ended December 28, 2025, primarily due to lower depreciation of equipment [102]. Income and Taxes - Total income tax expense for the three months ended December 28, 2025, was $205 thousand, up from $144 thousand in the prior year, and for the six months ended December 28, 2025, it was $411 thousand, compared to $313 thousand in the prior year [105]. - Basic net income per share remained stable at $0.04 for the three months ended December 28, 2025, with net income of $0.6 million on revenues of $3.0 million, compared to $2.9 million in the prior year [107]. - Basic net income per share increased by $0.01 to $0.09 for the six months ended December 28, 2025, with net income of $1.3 million on revenues of $6.3 million, compared to $5.9 million in the prior year [108]. Cash Flow - Cash provided by operating activities was $0.9 million for the six months ended December 28, 2025, down from $1.2 million in the prior year, primarily due to increased prepaid expenses [111]. - Cash used in investing activities was $3.1 million for the six months ended December 28, 2025, compared to $1.1 million in the prior year, primarily due to decreased maturities of U.S. Treasury bills [112]. - Net cash used in financing activities was zero for the six months ended December 28, 2025, compared to $0.2 million in the prior year, which was primarily attributable to taxes paid on vested RSUs [113]. - Management believes that cash and short-term investments on hand, combined with net cash provided by operations, will be sufficient to fund operations for the next 12 months and beyond [114].

Exhibit 99.1 "NOV delivered a strong finish to 2025, capping off a year in which solid execution and market share gains mostly offset lower levels of industry spend," said Jose Bayardo, Chairman, President, and Chief Executive Officer. "The combination of our technology leadership across a diverse portfolio of critical products and services along with our efforts to improve operational efficiencies is evident in our results." NEWS Contact: Amie D'Ambrosio (713) 375-3826 FOR IMMEDIATE RELEASE NOV REPORTS FOU ...

(Exact name of registrant as specified in its charter) FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2026 INTELLIGENT BIO SOLUTIONS INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State of Incorporation) (Commission File Number) Delaware 001-39825 82-1512711 (IRS employer identification no.) 135 West, 41st Street, 5th Floor New York, NY 10036 (Address of principal exec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ................ to ...................... Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its chart ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 3, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 000-00121 KULICKE AND SOFFA INDUSTRIES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1498399 (State or other ju ...

Thursday, February 5, 2026 INVESTOR CONTACT: MEDIA CONTACT: VP, Investor Relations VP, Chief Communications Officer greg.peterson@agcocorp.com rachel.potts@agcocorp.com AGCO REPORTS FOURTH QUARTER AND 2025 FULL YEAR RESULTS DULUTH, GA – February 5 – AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, reported net sales of $2.9 billion for the fourth quarter of 2025, an increase of 1.1% compared to the fourth quarter of 2024. T ...